申请人:Synthelabo
公开号:US05512590A1
公开(公告)日:1996-04-30
The invention discloses compounds formula (I) ##STR1## in which n represents the number 1 or 2, X represents a hydrogen atom or indicates that the phenyl ring to which it is attached is substituted by one or two substituents independently chosen from halogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and hydroxyl, and R represents a hydrogen atom, a group of formula --CH.sub.2 --CO.sub.2 --R.sub.1 (in which R.sub.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group) or a group of formula --CH.sub.2 --CO--NR.sub.2 R.sub.3 (in which each of R.sub.2 and R.sub.3 is independently a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group), or a pharmaceutically acceptable salt thereof, processes for their preparation and their use in the treatment of disorders of GABAergic transmission.
该发明揭示了化合物的结构式(I)##STR1## 其中n代表数字1或2,X代表氢原子或表示苯环上被取代为一个或两个取代基(分别选择自卤素、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷氧基和羟基),R代表氢原子,一个具有结构式--CH.sub.2--CO.sub.2--R.sub.1的基团(其中R.sub.1代表氢原子或C.sub.1-C.sub.6烷基)或一个具有结构式--CH.sub.2--CO--NR.sub.2R.sub.3的基团(其中R.sub.2和R.sub.3中的每一个都独立地是氢原子或C.sub.1-C.sub.3烷基),或其药学上可接受的盐,以及它们的制备方法和在GABA能传递障碍的治疗中的用途。